Answers are grounded in this paper and cite their sources.
Stakeholders in the field are aware of the exponential growth in gene and cell therapy development since 2014 but have not had at their fingertips comprehensive details on the pipeline. Those details include the magnitude of development—3,474 gene and cell therapies in development globally from the preclinical through pre-registration stages, 1,835 of which are in vivo and ex vivo gene therapies—and the breakdown by factors such as modality and therapeutic area. For example, 1,300 gene and cell therapy candidates are in development for oncology indications, 435 gene therapies are in development for non-oncology rare diseases, and the top non-oncology therapies under development for rare diseases are for retinitis pigmentosa, hemophilia A, amyotrophic lateral sclerosis, Duchenne muscular dystrophy, and sickle cell disease. In the gene therapy category alone, 17 therapies are approved for use in 12 countries plus the European Union (as of the end of the second quarter of 2021).
No takes yet. Share an insight, caveat, or question.
Foss-Campbell et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: